Efficacy and safety of combination therapy with Alfuzosin (Alfuprost® MR) and Solifenacin (Vesigamp) in patients with benign prostatic hyperplasia and overactive bladder: first results of the observational multicenter «Aviator» study
Автор: Sivkov A.V., Romikh V.V., Panteleev V.V., Kukushkina L.Yu., Zakharchenko A.V., Shashin M.N., Al-shukri A.S., Nashivochnikova N.A., Zavorina S.V., Ibishev Kh.S., Krainy P.S., Shikhotarov S.V., Shamarin A.A., Motin A.V., Khilai D.A.
Журнал: Экспериментальная и клиническая урология @ecuro
Рубрика: Андрология
Статья в выпуске: 4 т.16, 2023 года.
Бесплатный доступ
Introduction. Combination therapy of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with the use of a1-adrenoblockers and anticholinergic drugs has become the standard of treatment and is widely used in clinical practice.
Benign prostatic hyperplasia, lower urinary tract symptoms, overactive bladder, combined drug treatment, alfuzosin, solifenacin
Короткий адрес: https://sciup.org/142240794
IDR: 142240794 | DOI: 10.29188/2222-8543-2023-16-4-44-56
